Sign in
Not yet recruitingPhase 1

The TTM and ASM Trial

Key facts

Who runs it
National Taiwan University Hospital
Where
Taiwan1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 1
People taking part
100 people, planned
Started
17 Sept 2026
Expected to end
31 Jul 2029
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Prophylactic ASM
  • Hypothermic
  • Normothermic
  • ASM as needed
Record updated
7 October 2026

Who can take part

Age
18 years to 99 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Non-traumatic sudden cardiac arrest in adults
  • Sustained return of spontaneous circulation (ROSC) for at least 5 minutes
  • Admitted to the intensive care unit (ICU), remaining comatose and unable to follow commands
  • TIMECARD score indicating moderate-to-severe illness severity
  • Randomization and initiation of the intervention can be completed within 12 hours after ROSC

Who cannot take part

  • Patients with terminal cancer or cancer for which active treatment has been declined
  • Spontaneous hypothermia with a body temperature < 35°C; intracranial hemorrhage or massive bleeding
  • Age < 18 years; pregnant or breastfeeding women
  • TIMECARD score indicating mild risk
  • Pre-arrest Cerebral Performance Category (CPC) score of 3-4; receipt of extracorporeal cardiopulmonary resuscitation (ECPR; CPR with ECMO)
  • Refusal of participation by the patient's family

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 99 years old?

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Sudden cardiac arrest (SCA) remains one of the major challenges in clinical care.

Read full original descriptionShow less

Although improvements in resuscitation quality have increased the likelihood of return of spontaneous circulation (ROSC), most patients still fail to survive to hospital discharge, and neurological injury is the leading determinant of poor outcome. Hypoxic-ischemic encephalopathy caused by global cerebral hypoxia during cardiac arrest is a key contributor to long-term disability, and even survivors often experience substantial functional impairment, placing a significant burden on families and society. Targeted temperature management (TTM) has long been regarded as a cornerstone neuroprotective strategy; however, TTM and TTM2 trials reported no significant neurological difference between lower and higher temperature targets. However, these studies predominantly enrolled patients with relatively mild illness severity, and multiple real-world observational cohorts suggest that, among more severely ill resuscitated patients, lower target temperatures may still confer benefit. Consequently, the optimal temperature strategy in higher-risk subgroups remains uncertain. Seizures are another common manifestation of brain injury after cardiac arrest, occurring in approximately 20-30% of resuscitated patients and contributing to secondary neurological damage. Earlier trials evaluating prophylactic anti-seizure medication (ASM) (thiopental or diazepam/magnesium) did not demonstrate neurological benefit; however, these studies primarily focused on neuroprotection rather than seizure prevention, leaving a substantial evidence gap. Patients with moderate to severe disease severity-those at the highest risk of both cerebral injury and seizure occurrence-have never been specifically studied to determine whether personalized temperature selection or early short-term prophylactic ASM (e.g., valproic acid or levetiracetam) may provide clinical benefit. Accordingly, identifying the most appropriate temperature target for higher-risk patients and determining whether short-term prophylactic antiepileptic therapy can reduce seizure-related injury represent important unresolved questions in post-resuscitation care. The aim of this study is to conduct a prospective, multicenter, randomized clinical trial to evaluate whether, among comatose patients with moderate to severe risk after ROSC, specific TTM temperature strategies combined with early short-term prophylactic ASM can reduce postresuscitation seizure incidence and improve neurological outcomes. By addressing a population underrepresented in prior clinical trials-those at highest risk and most likely to benefit-this study aims to generate clinically meaningful evidence to guide temperature selection and prophylactic ASM after cardiac arrest. Evaluating these interventions in combination may provide a more comprehensive understanding of whether they reduce seizure burden, mitigate brain injury, and improve functional recovery.

The 4 groups in the trial

  • Hypothermic PPXTreatment being tested

    hypothermia + Prophylactic treatment

    Treatment: Prophylactic ASM and Hypothermic

  • Normothermic PPXExisting treatment, for comparison

    Normothermic + Prophylactic treatment

    Treatment: Prophylactic ASM and Normothermic

  • Hypothermic PRNExisting treatment, for comparison

    hypothermia + as needed

    Treatment: Hypothermic and ASM as needed

  • Normothermic PRNExisting treatment, for comparison

    Normothermic + as needed

    Treatment: Normothermic and ASM as needed

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Optimization of Neurological and Functional Recovery Following Cardiac Arrest
Criteria questions
Built from NCT07835802, who can take part
Record updated
7 October 2026